KemPharm Inc, which is investigating a drug therapy for idiopathic hypersomnia (IH), and the Hypersomnia Foundation, which engages, informs and champions the global community to improve the lives of people with IH and related sleep disorders, have partnered to support sleep disorder research and advocacy.
KemPharm is currently investigating KP1077 in a double-blind, placebo-controlled, randomized-withdrawal, dose-optimizing, multi-center phase 2 clinical trial evaluating the efficacy and safety of KP1077 for the treatment of IH. KemPharm expects to enroll approximately 48 adult patients with IH in more than 30 centers in the United States.
“We are pleased to be working in coordination with the Hypersomnia Foundation to increase awareness and knowledge of idiopathic hypersomnia for patients, caregivers, and clinicians to better understand the condition and advance research, with the ultimate goal of faster diagnosis and improved outcomes,” says Richard W. Pascoe, CEO of KemPharm, in a release. “IH is a rare sleep disorder for which few treatment options exist. We believe KP1077 has the potential to address the most debilitating symptoms of IH, and we look forward to advancing the recently initiated phase 2 clinical trial of KP1077 in IH with support from patient groups, including the Hypersomnia Foundation.”
Claire Crisp, MFA, CEO of the Hypersomnia Foundation, says in a release, “We are deeply grateful for the work KemPharm is doing to advance treatments for our community at such a time when pharmacological options for people with IH are so desperately lacking. Support from sponsors like KemPharm are key to our efforts to advocate for and support those dealing with debilitating sleep disorders.”